1. Home
  2. ALLO vs GAU Comparison

ALLO vs GAU Comparison

Compare ALLO & GAU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • GAU
  • Stock Information
  • Founded
  • ALLO 2017
  • GAU 1999
  • Country
  • ALLO United States
  • GAU Canada
  • Employees
  • ALLO N/A
  • GAU N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • GAU
  • Sector
  • ALLO Health Care
  • GAU
  • Exchange
  • ALLO Nasdaq
  • GAU Nasdaq
  • Market Cap
  • ALLO 338.9M
  • GAU 344.6M
  • IPO Year
  • ALLO 2018
  • GAU N/A
  • Fundamental
  • Price
  • ALLO $1.55
  • GAU $1.32
  • Analyst Decision
  • ALLO Strong Buy
  • GAU Strong Buy
  • Analyst Count
  • ALLO 10
  • GAU 1
  • Target Price
  • ALLO $9.66
  • GAU $2.80
  • AVG Volume (30 Days)
  • ALLO 2.6M
  • GAU 1.1M
  • Earning Date
  • ALLO 05-12-2025
  • GAU 05-14-2025
  • Dividend Yield
  • ALLO N/A
  • GAU N/A
  • EPS Growth
  • ALLO N/A
  • GAU N/A
  • EPS
  • ALLO N/A
  • GAU 0.02
  • Revenue
  • ALLO $22,000.00
  • GAU $231,339,000.00
  • Revenue This Year
  • ALLO N/A
  • GAU $58.96
  • Revenue Next Year
  • ALLO $9.07
  • GAU $39.24
  • P/E Ratio
  • ALLO N/A
  • GAU $56.90
  • Revenue Growth
  • ALLO N/A
  • GAU N/A
  • 52 Week Low
  • ALLO $1.23
  • GAU $1.00
  • 52 Week High
  • ALLO $3.78
  • GAU $2.00
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 49.84
  • GAU 53.09
  • Support Level
  • ALLO $1.38
  • GAU $1.26
  • Resistance Level
  • ALLO $1.75
  • GAU $1.37
  • Average True Range (ATR)
  • ALLO 0.13
  • GAU 0.09
  • MACD
  • ALLO 0.04
  • GAU 0.01
  • Stochastic Oscillator
  • ALLO 61.54
  • GAU 78.05

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

About GAU Galiano Gold Inc.

Galiano Gold Inc is focused on building a sustainable business capable of long term value creation for its stakeholders through a combination of exploration, accretive acquisitions, and disciplined deployment of its financial resources. The company currently operates and manages: Nkran, Esaase, Abore and Miradani North, multiple satellite deposits and exploration projects located on the Asankrangwa Gold Belt in the Amansie West District of the Republic of Ghana (Ghana), West Africa.

Share on Social Networks: